The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
 
Yuangyuan Zhao
No Relationships to Disclose
 
Wenfeng Fang
No Relationships to Disclose
 
Yunpeng Yang
No Relationships to Disclose
 
Jianhua Chen
No Relationships to Disclose
 
Li Zhuang
No Relationships to Disclose
 
Yingying Du
No Relationships to Disclose
 
Qitao Yu
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Wu Zhuang
No Relationships to Disclose
 
Ming Zhou
No Relationships to Disclose
 
Weidong Zhang
No Relationships to Disclose
 
Yu Zhang
No Relationships to Disclose
 
Yixin Wan
No Relationships to Disclose
 
Ziping Wang
No Relationships to Disclose
 
Lin Wang
No Relationships to Disclose
 
Yu Xia
No Relationships to Disclose
 
Baiyong Li
No Relationships to Disclose
 
Zhongmin Maxwell Wang
No Relationships to Disclose
 
Weifeng Song
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)